Building Block Catalogue
225 Thousand compounds in stock
Original and unique
Make-on-demand
Building Blocks
210 Million novel building blocks
Reliable supply
Custom Synthesis
Over 650 highly skillful chemists
Unique synthesis technologies
Library Synthesis
14 Billion REAL compounds and
Custom Library Synthesis
FTE Chemistry Support
On site access to all Enamine stock BB’s
Highly flexible arrangements
2 000 new building blocks are synthesized monthly. Here is an important update to our MedChem Highlights from February 2021
Recent News
24 February 2021 Press Releases
Enamine extend collaboration with prominent Swiss Biotech
A new multi-year drug discovery agreement will focus on CNS drug discovery
Kyiv, Ukraine, February 24 2021 - Enamine Ltd. a provider of drug discovery services empowered with the world’s largest collections of building blocks, fragments and screening compounds announced today that it has extended its long-standing research collaboration with Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company specialized in allosteric modulation-based drug discovery and development. Enamine is providing Addex with its integrated capability in medicinal chemistry, pharmacology and ADME/PK (Absorption, Distribution, Metabolism, Excretion/Pharmacokinetics) to efficiently support Addex’ small molecule CNS drug discovery programs.
Read press release15 January 2021 News
Open positions for Postdocs and Research Scientists
We have several Postdoc positions in organic chemistry to work at Enamine Ltd. (Ukraine, Kyiv) on a ERC-project “Saturated bioisosteres of benzene.” Start: 1 April 2021 (or later).
Please, send the application documents (motivation letter, CV, list of publications, recommendation letters) to Pavel.MykhailiukATmail.enamine.net
11 December 2020 News
ERC Consolidator Grant project 2020
Congratulations to Pavel Mykhailiuk, Chief Scientific Officer at Enamine, for receiving ERC Consolidator Grant funding for the Project: BENOVELTY - Saturated bioisosteres of benzene and their application in drug design.
The research will be carried out at Enamine Ltd in Ukraine, a global provider of chemical and biological services to biotech companies, academic institutions and research organisations.